The Dangers of Expanding HIV's Host Range

Scientists attending the Asilomar conference at Pacific Grove, Calif., in February 1975, made history by expressing public concern about the then newly recognized opportunities for splicing DNA artificially from one organism to another. Some possibilities—such as the introduction into the ubiquitous Escherichia coli of genes coding for botulinum toxin—were seen as so risky that they would never even be attempted. But many other fears ventilated at that time have proved to be un-fou

Written byAlexander Kohn
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Scientists attending the Asilomar conference at Pacific Grove, Calif., in February 1975, made history by expressing public concern about the then newly recognized opportunities for splicing DNA artificially from one organism to another. Some possibilities—such as the introduction into the ubiquitous Escherichia coli of genes coding for botulinum toxin—were seen as so risky that they would never even be attempted. But many other fears ventilated at that time have proved to be un-founded. Most researchers now believe that the products of recombinant DNA research are most unlikely to upset an organic world that took millions of years to develop and maintain.

Nevertheless, our vigilance should not be impaired by a false sense of security. Against that background, there is one type of genetic manipulation I believe should be questioned. The subject of this research is human immunodeficiency virus (HIV), which is responsible for AIDS, now spreading throughout the world as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies